Revenue declined 1% year-over-year to 17.8 MSEK, with EBITDA turning negative due to one-off costs from the Amvina acquisition. Despite a challenging market, Q2 sales are up 20% so far, and the company maintains a strong balance sheet.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.